Earnings Call · Q4 FY2024·2025-03-24

Q4 24EPS +56.60%·Rev n/aQ3 24EPS -16.80%·Rev n/aQ2 24EPS +32.27%·Rev n/aQ1 24EPS +42.78%·Rev n/a⚠ consensus missing

Moleculin Biotech, Inc. MBRX

Walter Klemp — Chief Executive Officer

John Paul Waymack — Chief Medical Officer

Jonathan Foster — Chief Financial Officer

−2.8%1d on move date−4.5% vs SPY3d−1.8%5d−4.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MBRX calls or request research access.

More MBRX calls Browse calls Request research access